

## Correlation Of Urinary Collagen IV: Urinary Albumin Ratio In The Prediction Of Preeclampsia

Asma-UL-Hosna<sup>1</sup>, Asma Rumanaz Shahid<sup>2</sup>, A.K.M. Mohiuddin Bhuyan<sup>3</sup>, Hosna Zari Thamina<sup>5</sup>  
Mohammad Salman<sup>4</sup>, Md. Ashraf Uddin Sultan<sup>3</sup> Shapla Akhter<sup>6</sup>

<sup>1</sup>Department of Obs & Gynae, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka.

<sup>2</sup>Department of Obs & Gynae, Dhaka Medical College Hospital (DMCH), Dhaka.

<sup>3</sup>Department of Cardiology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka.

<sup>4</sup>Anwer Khan Modern Medical College, Dhanmondi, Dhaka.

<sup>5</sup>Consultant, Chuadanga Sadar Hospital, Chuadanga

<sup>6</sup>Department of Obs & Gynae, Institute of Child and Maternal Health Matuail (ICMH), Dhaka

### Address for Correspondence

Dr. Asma-UL-Hosna, Assistant Professor, Department of Obs & Gynae, Bangabandhu Sheikh Mujib Medical University (BSMMU).

E-mail: dr\_akmmb@yahoo.com

### Abstract

The purpose of this study was to assess the value of MA in the prediction of PE and also to compare urinary collagen IV with MA in this prediction. A total of 200 subjects (age 25±4 years, M±SC), were selected in their early pregnancy (10 to 14 weeks). Blood glucose, serum lipids, serum and urinary creatinine, urinary albumin and urinary collagen IV were measured in these subjects and they were followed up to the term for the possible development of PE, MA was defined by albumin creatinine ratio (ACR) above 32mg/g and high urinary collagen IV was defined by values above the cut-off point 2.54 ng/ml determined by the median value of the controls. The data were analyzed by grouping the subjects who developed PE in later stages of pregnancy (the PE group) and those who did not develop PE in later stages (the control group).

Out of 200 subjects 94 were primigravida and 106 were multigravida. From the total subjects 16 developed PE, which shows a prevalence of about 8.4%. The PE group showed a relatively higher value of ACR as compared to control group. 106 subjects had MA out of which 13 developed PE. The sensitivity of ACR in predicting the development of PE was 80%, specificity 49.54%, PPV 12.69% and NPV 96.42%. Regarding urinary collagen IV the PE group showed no significant difference with the value of the control group. 103 subjects had high urinary collagen IV and out of them 11 developed PE. The sensitivity of high urinary collagen IV in prediction PE was found to have no significant difference with ACR in this respect. The data suggest the following conclusions:

- Early pregnancy levels of microalbuminuria and urinary collagen IV can be used as predictors of PE with high negative value.
- Urinary collagen IV has no added advantage over MA in this respect.

**Keywords :** MA-Micro

### Introduction

Hypertensive status in pregnancy include preeclampsia (PE)- eclampsia, chronic hypertension (either essential or secondary to renal disease, endocrine disease or other causes), chronic hypertension with superimposed PE and gestational hypertension<sup>1</sup>.

PE as hypertension accompanied by proteinuria presenting after the 20<sup>th</sup> week of gestation. A diagnosis of eclampsia is made when a patient demonstrates seizure activity or coma in addition to signs and symptoms of PE<sup>2</sup>.

PE occurs in about 6% of the general population; the incidence varies with geographic location (Reynolds et al 2003). In the developing countries like Bangladesh, the incidence is expected to be higher<sup>28</sup>.

PE is the second leading cause of maternal mortality con-

stituting 12% to 18% of pregnancy related maternal deaths.<sup>5</sup> Women with PE are at increased risk for such complications as abruptio placenta, acute renal failure, cerebral hemorrhage, disseminated intravascular coagulation, pulmonary edema, circulatory collapse and eclampsia<sup>27</sup>. PE is strongly associated with adverse pregnancy outcome<sup>32</sup>.

For practical purpose, most studies or potential screening test for PE have relied on clinical criteria to confirm the diagnosis. Many proposed screening tests have been found suitable for early detection of PE<sup>10</sup>. Clinical history is the simplest test. Others are average second trimester MAP > 90 mm of Hg, angiotension infusion test, rollover test, uterine artery doppler wave forms at 18-22 weeks<sup>30</sup>.

Second trimester MAP has low sensitivity and low positive predictive value as an indicator of future development of PE<sup>1</sup>. Angiotension II infusion test has a high incidence of

false negative and false positive results moreover it has been found to be unsuitable and impractical for the routine evaluation of pregnant women. Supine pressor 'rollover' examination has poor sensitivity, poor specificity and limited clinical value.

Biochemical tests suggested for prediction of PE urinary calcium, urinary kallikrein to creatinine ratio, serum AFP/hcG, plasma fibronectin, serum inhibin, serum urate, hematocrit, antihrombin III and plasminogen activator inhibitors<sup>1,2</sup>. In most cases of PE, all the above factors are found to be associated in varying frequency and combination. It is clear that no test found to be associated in varying frequency and combination. It is clear that no test reliably predicts PE.<sup>29</sup> Further studies are going on to detect an effective and practical early predictor of PE which will be of 'gold standard'.

All the previous studies suggested that concluded that microalbuminuria cannot be used to predict which normal woman will develop PE. These controversial results promoted the interest to detect a more suitable predictor for PE.

More recent studies have claimed that increased urinary levels of collagen IV are detected in conditions where glomerular injury is found particularly in diabetic nephropathy<sup>22</sup>.

The aim of this study was to detect some biochemical marker that can successfully predict PE. So, here my attempt was to detect the predictive value of urinary collagen IV levels in pregnant women who are free from symptoms of PE. detection of urinary collagen IV levels in pregnant women might have more predictive value in subsequent development of PE than microalbuminuria.

### Aims And Objective

The objectives of the present study were:

To measure the urinary levels of albumin and collagen IV during first trimester of pregnancy and to determine whether the presence of the above molecules in the urine of asymptomatic pregnant women can predict the subsequent development of PE.

### Materials And Methods

#### Place of the study:

The prospective study was conducted at the Department of Obstetrics and Gynecology, DMCH, BSMMU, BIRDEM, during the period of Jan 2007 to December 2008.

#### Subjects

A total number of 200 pregnant women at 10-14 weeks of pregnancy were selected on the basis of availability.

#### Inclusion criteria:

- All women at their 10 to 14 weeks of pregnancy.
- Women at their reproductive age, having no other complications or associated disease.

#### Results

In the present study, 200 women were included. All were at their 10-14 weeks of pregnancy without any complication or any known risk factors for developing preeclampsia. Among them PE developed in 16 patients. The rest 184 patients remained normotensive (Controls). The prevalence of PE among the study group was 8%.

**Table- 1: Anthropometric and clinical parameters of the**

Group	Age Years	BMI kg/m <sup>2</sup>	SBP mmHg	DBP mmHg	MAP mmHg
Control n=184	25±4	22.68±3.49	105±11	67±9	80±8
PE n= 16	26±5	24.54±4.35	134±11	92±10	106±9
t/p value					
Control vs. PE	0.68/0.49	1.58/0.11	7.7/0.001	8.80/0.001	9.30/0.001

#### study subjects.

BMI, Body Mass Index; SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure; MAP, Mean Arterial Pressure; n, number of subjects. Results are expressed as mean ±SD, t/p value was calculated using by Student's unpaired t-test;

**Table- 2: Percentage of PE among Collagen IV and ACR positive case.**

	Total	Control %	PE	PE%
Coll-IV+	103	88.53	11	11.47
ACR +	106	87.30	13	12.69

Coll-IV, Urinary collagen IV; PE, Preeclampsia; ACR, Albumin Creatinine Ratio.

**Table-3 : The sensitivity, specificity and predictive values of ACR for PE.**

ACR	PE		Total
	+	-	
+	13	91	106
-	3	91	94
Total	16	184	200

**Table- 4: The sensitivity, specificity and predictive values of collagen IV for PE.**

Coll-IV	PE		Total
	+	-	
+	11	91	103
-	5	93	97
Total	16	184	200

**Table- 5: Comparison of collagen IV against ACR as a predictor of PE.**

Coll-IV	PE		Total
	+	-	
+	61	42	103
-	45	52	97
Total	106	94	200

### Discussion

Prediction of PE in the early stages of pregnancy can be very helpful in preventing the disorder or in decreasing its severity. It has, thus, become a major focus of research in PE.

An albumin excretion between 25 and 250 mg/day is defined as MA and its presence indicates glomerular dysfunction resulting from generalized microvascular damage<sup>1</sup>.

The sensitivity of prediction PE by measuring MA in early pregnancy varied between 50% to 68%, the specificity varied between 58 to 97%, PPV varied between 26 to 61% and the NPV varied between 87-94%<sup>8,10</sup>.

Out of 200 pregnant subjects screened 16 developed PE in later stages; thus the prevalence is about 8.4% which is little lower than the usual values in the developing world, but seems to be reasonable in an urban setting. The present data shows that the group of pregnant subjects who developed PE in later stages had significantly higher values of ACR as compared to cases who did not develop PE.

In the absence of reference range of ACR in early pregnancy the ACR cut-off point for normal subjects (32 mg/g) was taken as the cut-off point in our subjects.<sup>22</sup> Using this criteria 106 patients had MA, among whom 13 developed PE in later pregnancy and 93 did not develop PE.

The sensitivity of MA as a predictor of PE was found to be 80% which lies above the values reported by various authors. The specificity in the present study 49.54%, however, was slightly lower. The NPV in the present study was 96.42% which corresponds to the values of 94.40% as reported by Bar et al 1996 and the PPV was 12.69% which is much lower than that reported by Das et al (1996)<sup>3,13</sup>.

In the present study the urinary collagen IV level in the pregnant subjects who developed PE in later stages [2.74 (1.60-7.5) ng/ml, p= 0.244]. Since there is no published data on the reference ranges of urinary collagen IV in early pregnancy we used the median value in normal subjects (2.54 ng/ml) as a cut-off point. Using these criteria 103 (88.53%) patients had high collagen (IV) and out of those 11 (11.47%) developed PE in later pregnancy. The sensitivity of urinary collagen IV in predicting PE was 70%, specificity 50.50%, PPV 11.50% and NPV 94.8%.

### References

1. Arias F. Preeclampsia and Eclampsia. Practical Guide to High-Risk Pregnancy and Delivery. 2nd ed. United States of America: Mosby-Year Book, Inc; 1997; 183-209.
2. Beaulieu MD. Prevention of preeclampsia. In: Canadian Task Force on the Periodic Health Examination. Canadian Guide to Clinical Preventive Health Care. Ottawa: Health Canada, 1994; 136-43.
3. Bar J, Hod M, Erwan A, Friedman S, Boner G, Ovadia J. Microalbuminuria as an early predictor of hypertensive complications in pregnant women at high risk. *AMJ Kidney Dis* 1996; 28:2205.
4. Berlin M, Washington AE. Screening for Preeclampsia. For the U.S. Preventive Services Task Force. Guide to Clinical Preventive Services, 2nd ed. 2002.
5. Bolte AC, Geijn HP, Dekker GA. Pathophysiology of preeclampsia and the role of serotonin. Available from: URL:<http://www.sciencedirect.com>, 2000 April 21;
6. Brooks MB, Sayan AJ, Talavera F, Zwanger M, Halamka J, Connor RO. Pregnancy, Preeclampsia. *Medicine* [serial online] Available from: URL:<http://www.emedicine.com/EMERG/topic/796.htm> 2004 March 18;
7. Caritis S, Sibai B, Hauth J, Lindheimer M, Vandorsten P, Klebanoff M et al. Predictors of pre-eclampsia in women at high risk. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. *Am J Obstet Gynecol*. 1998 Oct; 179; 946-51.
8. Chappell LC, Seed PT, Briley A, Kelly FJ, Hunt BJ, Charnock-Jones DS et al. A longitudinal study of biochemical variables in women at risk of preeclampsia. *Am J Obstet Gynecol*. 2002 Jul; 187(1); 27-36.
9. Chavarria ME, Lara-Gonzalez L, Gonzalez-Gleason A, Sojo I, Reyes A. Maternal plasma cellular fibronectin concentrations in normal and pre-eclampsia pregnancies: a longitudinal study for early prediction of pre-eclampsia. *Am J Obstet Gynecol*. 2002 Sep; 187(3); 595-601.
10. Clausen T, Djurovic S, Henriksen T. Dyslipidemia in early second trimester is mainly a feature of women with early onset of pre-eclampsia. *Br J Obstet Gynaecol*. 2001 Oct; 108; 1081-87.
11. Cohen MP, Shearman CW, Lautenslanger GT. Serum type IV collagen in diabetic patients at risk for nephropathy. *Diabetes Care* 2001 Aug; 24(8); 1324-27.
12. Cunningham FG, Mac PC, Gant FN, Leven KJ, Gilstrap III LC, Hankins GDV et al. Hypertensive Disorders in Pregnancy. *Williams Obstetrics*. 20th ed. London; Prentice-Hall International, Inc, 1997; 693-744.
13. Das V, Bhargava T, Das SK, Pandey S. Microalbuminuria: a predictor of pregnancy-induced hypertension. *Br J Obstet Gynaecol*. 1996, 103; 928-30.

14. Fielding BA, Price DA, Houton CA. Enzyme immunoassay for urinary albumin. *Clin Chem* 1983; 29(2): 355-57.
15. Fraij BM. Transferrin and albumin excretion as a measure of glomerular function. *Clin Physiol Biochem*. 1989; 7: 296-302
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparatory ultra centrifuge. *Clin Chem*, 1972 June; 18:499-502.
17. Gibson P, Carson M, Talavera F, Smith CV, Gaupp FB, Shulman LP. Hypertension and pregnancy. *Medicine [serial online]* Available from:<http://www.emedicine.com/specialties/htm>. Retrieved: 2004 June 26.
18. Goldberg ME. Dose of compound A, not Seroflurane, determine changes in the biochemical markers of renal injury in healthy volunteers. *Anaesthesia and Analgesia*. 1999; 88 437-45.
19. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RF. Pathophysiology of Hypertension During Preeclampsia Linking Placental Ischemia With Endothelial Dysfunction. *Hypertension*. 2001 June 22; 38: 718.
20. Higby K, Suiter CR, Phelpa JV, Siler-Khodor T, Langer O. Normal values of urinary albumin and total protein excretion during pregnancy. *Am J Obstet Gynecol* 1994; 171:9849.
21. Krauss T, Emons G, Kuhn W, Augustin HG. Predictive value of routine circulating soluble endothelial cell adhesion molecule measurements during pregnancy. *Clin Chem*. 2002 Sep; 48(9): 1418-25.
22. Lijima T, Sujuki S, Sekijuka K, Hishika T, Yagme M, Jinde K et al. Follow-up study on urinary type IV collagen in patients with early stage diabetic nephropathy. *J Clin Lab Anal*. 1998; 12: 378-82
23. McCormick CP, Konen JC, Shihabi ZK. Microtransferrinuria and microalbuminuria in the diabetic human. *Clin Physiol Biochem*. 1990; 8: 538.
24. Mise H, Sagawa N, Matsumoto T, Yuga S, Nanno H, Itoh H et al. Augmented placental production of leptin in preeclampsia: possible involvement of placental hypoxia. *J Clin Endocrinol Metab*. 1998; 83(9): 3225-29.
25. Muller I, Hemmingsen L, Holm J. Diagnostic value of microalbuminuria in pre-eclampsia. *Clin Chim Acta* 1986; 157:29-58.
26. National High Blood Pressure Education Program Working Group. Report on high blood pressure in pregnancy. *Am J Obstet Gynecol* 1988; 163: 1691-1712
27. Redman CWG, Roberts JM. Management of preeclampsia. *Lancet* 1993; 341: 1451-54.
28. Reynold C, Mabie WC, Sibai BM, DeCherney AH, Nathan L. Hypertensive States of Pregnancy. In DeCherney AH, Nathan L (eds) *Current Obstetric & Gynecologic Diagnosis & Treatment*, 9th ed. New York: Mc Graw-Hill, 2003; 338-53.
29. Roberts JM. Preeclampsia: what we know and what we do not know. *Semin Perinatol*. 2000 Feb; 24(1): 24-28.
30. Roberts JM, Redman CWG. Preeclampsia: more than pregnancy-induced hypertension. *Lancet* 1993 June 5; 341: 1447-51.
31. Robson SC, Edmond DK. Hypertensive and renal disease in pregnancy. *Dewhurst's Textbook of Obstetrics and Gynaecology for Postgraduates*. 6th ed. United Kingdom: Blackwell Science Ltd; 1999. 166-85.